Alzheimer's disease (AD) is a devastating neurodegenerative disease characterized by memory loss.

       On July 16, 2023, the latest draft of AD diagnostic guidelines released by the Alzheimer's Association International Conference (AAIC) included biomarkers reflecting Aβ accumulation (Aβ42/40) and tau pathology biomarkers (p-Tau181; p-Tau217). It also involves non-specific biomarkers of other neurodegenerative diseases: biomarkers of neuronal degeneration or damage (N) (NfL) and inflammatory/immune biomarkers (I) (GFAP) The accumulation of amyloid beta (Aβ) plaques in the brain is one of the typical pathophysiological characteristics of AD, and the Aβ42/40 ratio is used as a reference indicator in clinical practice.

【 Protein three-dimensional simulation diagram 】

        Hyperphosphorylation of Tau protein leads to the formation of neurofibrillary tangles (NFTs) in neurons and glial cells. In clinical practice, p-Tau181, p-Tau217, and p-Tau231 are used as reference indicators.

Lifebio Alzheimer's disease related antibody reagents

Lifebio Alzheimer's disease related antigen standards

       Lifebio provides antibody reagents and antigen standards related to clinical detection of biomarkers, and also provides detailed bioinformatics information such as amino acids at antibody binding sites.